Tier 4 — mechanistic
Fisetin to Improve Vascular Function in Older Adults
ClinicalTrials.gov trial registry record
2023
Bibliography
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
- Funding
- Sponsor: University of Colorado, Boulder. Collaborator: American Heart Association.
- Competing interests
- Not reported in the ClinicalTrials.gov registry record; no peer-reviewed results manuscript is available for a manuscript-level conflict-of-interest statement.
Study snapshot
| Design | Randomized, double-blind, placebo-controlled, parallel-group Phase 1/2 trial with triple masking of participant, investigator, and outcomes assessor. |
|---|---|
| Model | Adults aged 65 years and older; healthy volunteers accepted. |
| Sample | Estimated enrollment: 70 participants. |
| Intervention | Fisetin 2 mg/kg/day for 3 consecutive days, followed by a second 3-day course two weeks later, versus identical placebo. |
| Duration | Study start 2023-09-25; primary completion estimated 2026-03-31; study completion estimated 2027-03-31. Primary vascular endpoint assessed at 1 month. |
| Endpoints | Primary: change in brachial artery flow-mediated dilation at 1 month; Secondary: change in carotid-femoral pulse wave velocity at 1 month; Endothelial and blood-cell senescence markers including p16 and p21; Circulating SASP factors; Mitochondrial oxidative-stress contribution to endothelial dysfunction; Safety, tolerability and adherence |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- How and When to Take FisetinHuman fisetin studies use multiple schedules, and neither a high-fat meal nor morning dosing has been proved superior. This guide separates published...Read analysis
- Fisetin Dosage: What Human Studies Actually UseThere is no single established fisetin dose. Human studies have used 100 mg/day, 200–800 mg/day, 2 mg/kg intermittent dosing, ~20 mg/kg senolytic...Read analysis
- Fisetin: A Clinician's Guide to Evidence, Dose & SafetyFisetin is a plant flavonol with senolytic activity in selected cell and animal models. Human research now spans continuous low-dose regimens, intermittent...Read analysis
- Fisetin Pulse Dosing: What Human Trials Actually UseThere is no single Mayo Clinic fisetin protocol. Human trials use one-, two- and three-day pulses, with repeat intervals ranging from one...Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
